ZYBT NASDAQ
Zhengye Biotechnology Holding Limited
1W: -6.9%
1M: -25.1%
3M: +75.3%
YTD: +8.0%
1Y: -49.8%
$1.24
-0.02 (-1.59%)
Weekly Expected Move ±7.6%
$1
$1
$1
$1
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$186M
-12.0% ▼
3Y CAGR: -4.5%
Gross Profit
$91M
-29.7% ▼
3Y CAGR: -10.0%
Operating Income
$16M
-63.5% ▼
3Y CAGR: -32.0%
Net Income
$11M
-64.0% ▼
3Y CAGR: -33.8%
EPS (Diluted)
$0.00
+0.0% ▲
EBITDA
$43M
-40.9% ▼
3Y CAGR: -15.3%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
| Revenue | $214M | $260M | $212M | $186M |
| YoY Growth | +0.0% | +21.6% | -18.7% | -12.0% |
| Cost of Revenue | $89M | $107M | $82M | $95M |
| Gross Profit | $125M | $154M | $130M | $91M |
| Gross Margin | 58.6% | 59.0% | 61.4% | 49.0% |
| R&D Expenses | $11M | $13M | $12M | $13M |
| SG&A Expenses | $58M | $64M | $67M | $64M |
| Operating Expenses | $73M | $88M | $85M | $75M |
| Operating Income | $52M | $66M | $45M | $16M |
| Operating Margin | 24.5% | 25.3% | 21.3% | 8.8% |
| Interest Expense | $1M | $3M | $4M | $4M |
| Income Before Tax | $53M | $64M | $44M | $14M |
| Tax Expense | $7M | $8M | $6M | $924K |
| Net Income | $39M | $47M | $31M | $11M |
| Net Margin | 18.2% | 18.0% | 14.9% | 6.1% |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
| EBITDA | $70M | $86M | $72M | $43M |
| Shares Outstanding | 0 | 0 | 0 | 0 |